An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new report from researchers at NYU Langone looked at how often doctors are prescribing GLP-1 drugs—medicines like Ozempic and Wegovy that help with weight— to young children with obesity in the United States. What they found is that use in this age group is still uncommon, but prescriptions have been increasing quickly over a recent period. The story is mostly about a trend: rare now, rising fast. GLP-1 drugs are a class of medicines that copy a natural chemical in the body called glucagon-like peptide-1. That chemical helps control blood sugar, slows how fast the stomach empties, and tells the brain to feel less hungry. Brands you may have heard of, such as Ozempic and Wegovy, contain versions of this chemical. They were developed for adults with type 2 diabetes or for weight management, and researchers are now watching how and whether they're being used for younger kids. The research behind the news is an observational look at prescription records and medical data, not a randomized controlled trial. That means the team counted how many prescriptions were written for children with obesity and tracked the change over time. They report that absolute numbers remain low—only a small fraction of children with obesity were prescribed GLP-1 drugs—but the rate of increase is steep. The study tells us about prescribing patterns and trends, not about long-term safety or effectiveness in young children. This matters because obesity in childhood can have lasting health effects, and parents and doctors are looking for effective tools. If GLP-1 prescriptions for kids are rising, it signals changing medical practice and demand. Families of children with severe obesity, pediatricians, and policymakers will want to know this trend exists because it could affect access, insurance coverage, and how pediatric obesity is treated in clinics. There are important caveats. These drugs were mainly tested and approved for adults; the evidence base for safety and long-term effects in young children is limited. Side effects in adults include nausea, stomach upset, and sometimes more serious issues; how often or severe these are in kids is less well understood. We also don’t know from prescription counts whether doctors are following pediatric guidelines, what dosing they use, or how outcomes are tracked. Finally, access and cost can be barriers, and off-label use (prescribing a drug outside the age or condition it was approved for) raises ethical and regulatory questions. Bottom line: Prescribing of GLP-1 drugs to young children with obesity is still uncommon but growing fast, which is important to know—yet significant questions about safety, long-term benefits, and appropriate use in kids remain unanswered.
Source: NYU Langone Health